[HTML][HTML] The paradox of HIV blood–brain barrier penetrance and antiretroviral drug delivery deficiencies
HIV attacks the body's immune cells, frequently compromises the integrity of the blood–brain
barrier (BBB), and infects the CNS in the early stages of infection. Dysfunction of the BBB …
barrier (BBB), and infects the CNS in the early stages of infection. Dysfunction of the BBB …
Long-acting parenteral drug delivery systems for the treatment of chronic diseases
The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …
extended duration. However, the need for daily dosing can lead to nonadherence to the …
[HTML][HTML] Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice
Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from
infected cells and tissues. Here, sequential long-acting slow-effective release antiviral …
infected cells and tissues. Here, sequential long-acting slow-effective release antiviral …
Prodrug approaches for the development of a long-acting drug delivery systems
ST Chien, IT Suydam, KA Woodrow - Advanced Drug Delivery Reviews, 2023 - Elsevier
Long-acting formulations are designed to reduce dosing frequency and simplify dosing
schedules by providing an extended duration of action. One approach to obtain long-acting …
schedules by providing an extended duration of action. One approach to obtain long-acting …
[HTML][HTML] Creation of a long-acting nanoformulated dolutegravir
Potent antiretroviral activities and a barrier to viral resistance characterize the human
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …
CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice
Treatment of HIV-1ADA-infected CD34+ NSG-humanized mice with long-acting ester
prodrugs of cabotegravir, lamivudine, and abacavir in combination with native rilpivirine was …
prodrugs of cabotegravir, lamivudine, and abacavir in combination with native rilpivirine was …
[HTML][HTML] Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life …
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life …
Self-assembled lipid–prodrug nanoparticles
Nanomedicines suffer from poor drug loading and uncontrolled 'burst release'after
administration. Combining prodrug strategies with nanostructured carriers can help to …
administration. Combining prodrug strategies with nanostructured carriers can help to …
[HTML][HTML] A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy
Background Despite improved clinical outcomes seen following antiretroviral therapy (ART),
resting CD4+ T cells continue to harbor latent human immunodeficiency virus type one (HIV …
resting CD4+ T cells continue to harbor latent human immunodeficiency virus type one (HIV …
[HTML][HTML] Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …